Prognostic score for recurrence after Whipple's pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort.
暂无分享,去创建一个
B. Nordlinger | P. Rougier | J. Vaillant | A. Sauvanet | B. Dousset | P. Hammel | J. Taieb | A. Berger | R. Coriat | C. Locher | D. Malka | J. Bachet | F. Paye | T. André | T. Voron | O. Colussi | T. Aparicio | F. Bonnetain | C. Locher | A. Pozet | D. Cojean Zeleck | L. Tchinou | D. C. Zeleck
[1] B. Gayet,et al. Predictors of Long-Term Survival Following Resection for Ampullary Carcinoma: A Large Retrospective French Multicentric Study , 2014, Pancreas.
[2] K. Lillemoe,et al. Pancreatic Ductal Adenocarcinoma: Is There a Survival Difference for R1 Resections Versus Locally Advanced Unresectable Tumors? What Is a “True” R0 Resection? , 2013, Annals of surgery.
[3] S. Morini,et al. Carcinoma of the Ampulla of Vater: Morphological and Immunophenotypical Classification Predicts Overall Survival , 2013, Pancreas.
[4] O. Clausen,et al. Intestinal-type and Pancreatobiliary-type Adenocarcinomas: How Does Ampullary Carcinoma Differ from Other Periampullary Malignancies? , 2013, Annals of Surgical Oncology.
[5] Jiahong Dong,et al. [Predictors of recurrence after pancreaticoduodenectomy for carcinoma of the ampulla of Vater]. , 2012, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.
[6] M. Büchler,et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. , 2012, JAMA.
[7] D. Choi,et al. Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer , 2012, Journal of surgical oncology.
[8] O. Clausen,et al. Prognostic Relevance of Number and Ratio of Metastatic Lymph Nodes in Resected Pancreatic, Ampullary, and Distal Bile Duct Carcinomas , 2012, Annals of Surgical Oncology.
[9] C. Willett,et al. Carcinoma of the Ampulla of Vater: Patterns of Failure Following Resection and Benefit of Chemoradiotherapy , 2012, Annals of Surgical Oncology.
[10] J. Cameron,et al. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital - Mayo Clinic collaborative study , 2011, Radiation oncology.
[11] C. Yeo,et al. The Influence of Prognostic Factors and Adjuvant Chemoradiation on Survival After Pancreaticoduodenectomy for Ampullary Carcinoma , 2011, Journal of Gastrointestinal Surgery.
[12] T. Ha,et al. Pattern Analysis of Lymph Node Metastasis and the Prognostic Importance of Number of Metastatic Nodes in Ampullary Adenocarcinoma , 2011, The American surgeon.
[13] T. Wilson,et al. Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion. , 2010, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[14] M. Ward,et al. Effect of Meeting Leapfrog Volume Thresholds on Complication Rates Following Complex Surgical Procedures , 2010, Annals of surgery.
[15] M. C. Machado,et al. Lymph Node Involvement and Not the Histophatologic Subtype Is Correlated with Outcome After Resection of Adenocarcinoma of the Ampulla of Vater , 2010, Journal of Gastrointestinal Surgery.
[16] M. Bloomston,et al. Predictors of Survival in Periampullary Cancers Following Pancreaticoduodenectomy , 2010, Annals of Surgical Oncology.
[17] J. Galloway,et al. Important Prognostic Factors in Adenocarcinoma of the Ampulla of Vater , 2009, The American surgeon.
[18] J. Buckels,et al. Assessment of survival advantage in ampullary carcinoma in relation to tumour biology and morphology. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[19] Jeffrey S. Morris,et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Gulbinas,et al. Tumor-related factors and patient's age influence survival after resection for ampullary adenocarcinoma. , 2008, Journal of hepato-biliary-pancreatic surgery.
[21] H. Ohge,et al. Prognostic Impact of Perineural Invasion Following Pancreatoduodenectomy With Lymphadenectomy for Ampullary Carcinoma , 2008, Digestive Diseases and Sciences.
[22] K. Hatakeyama,et al. Number of positive lymph nodes independently affects long-term survival after resection in patients with ampullary carcinoma. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[23] Helen Hickey,et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.
[24] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[25] D. Kerr,et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial , 2001, The Lancet.
[26] D. Henson,et al. Tumors of the Gallbladder, Extrahepatic Bile Ducts and Ampulla of Vater , 2000 .
[27] F. Sellner,et al. Implications of histological grade of tumour for the prognosis of radically resected periampullary adenocarcinoma. , 1999, The European journal of surgery = Acta chirurgica.
[28] J. Campion,et al. Diagnosis and Therapy for Ampullary Tumors: 63 Cases , 1996, World Journal of Surgery.
[29] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.